Q4 2022
Released Mar 31, 2023, before the open
10-K filed Mar 31, 2023, 90 days after period end · 0001789769-23-000035
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$53.84M-$53.84M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$56,799,000N/M
Operating Cash Flowderived-$36,976,000N/M
Free Cash Flowderived-$49,988,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Revenue | — | $0.00 | $0.00 |
| Net Income | -$53.84M | -$55.35M | -$17.19M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR